Developing vaccines for infectious diseases including SARS-CoV-2
Task V25: PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS-COV-2
This study is working on creating and improving vaccines to help protect people from infectious diseases like COVID-19, and it aims to make new vaccines that could also fight against bioterrorism threats, so everyone can benefit from better protection in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project ID | NIH-10168821 on NIH RePORTER |
What this research studies
This research focuses on the development and optimization of vaccines and biologics to combat infectious diseases, including SARS-CoV-2. It involves planning and feasibility assessments, as well as the manufacturing of vaccine components in compliance with regulatory standards. The project aims to support the introduction of new vaccines against bioterrorism threats and emerging infectious diseases through rigorous testing and evaluation. Patients may benefit from the advancements in vaccine technology and the potential for new vaccines to be developed.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk for infectious diseases or those involved in clinical trials for new vaccines.
Not a fit: Patients who are not at risk for infectious diseases or those who do not meet the criteria for clinical trial participation may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against infectious diseases, improving public health outcomes.
How similar studies have performed: Other research has shown success in developing vaccines using similar methodologies, indicating a promising approach to vaccine development.
Where this research is happening
Dessau-Rosslau, Germany
- Idt Biologika Gmbh — Dessau-Rosslau, Germany (Active)
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.